SMO Mutation

CI-VAR-00002663Explore in graph →CIViC 300

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Basal Cell Carcinoma3
SMO Mutation	Arsenic Trioxide + PSISubstitutes	Predictive	D	Supports Sensitivity Response	4	accepted	EID747 Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-ι/λ/GLI inhibitor) or a… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 · Open in CIViC	civic
SMO Mutation	Vismodegib	Predictive	B	Supports Resistance	4	accepted	EID746 In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib. SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patie… (full text at CIViC) PMID 25759020 · Atwood et al., 2015 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
SMO Mutation	Vismodegib	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID5979 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one p… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic